ROCKVILLE, Md., Dec. 21, 2018 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biologic aggregation focused on developing and commercializing articles for the analysis of axial afraid arrangement diseases, today appear that the Company’s administration will present an overview and Aggregation amend as able-bodied as host broker affairs at the 37th Annual J.P. Morgan Healthcare Conference.
Date: Wednesday, January 9, 2019
Time: 10:30 a.m. PT (1:30 p.m. ET)
Place: Westin St. Francis Hotel, San Francisco, Calif.
Investors absorbed in alignment a affair with the Company’s administration during this appointment should acquaintance the appointment coordinator.
A alive webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Broker Relations Section on the Company’s website at Media An archived epitomize of the webcast will be accessible for 60 canicule on the Company’s website afterwards the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biologic aggregation focused on developing and commercializing articles for the analysis of axial afraid arrangement (CNS) diseases. The Aggregation currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of cephalalgia and the analysis of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the analysis of fractional seizures. The Aggregation is additionally developing several artefact candidates to abode ample opportunities in the CNS market, including SPN-810 for the analysis of Impulsive Aggression in ADHD patients, SPN-812 for the analysis of ADHD and SPN-604 for the analysis of bipolar disorder.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Office: (443) 213-0505
Mobile: (443) 377-4767